Maybe people were thinking of the INFI release. That came out today- "Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer" and it was no better than placebo. So HSP90 will get a bad rap and SNTA might take a hit.
Nice try basher. But tell me, how does the elimination of competition do anything but help us, especially when we passed through phase 2 and are into phase 3? There are shorts short here who are long on INFI. And any big pharma out there looking for this type of drug has just narrowed its list and we are still on it. Looks positive to me. Keep trying, but don't quit the day job.